Clinical analysis of four therapies of unexplained spontaneous abortion

Abstract

Objective To evaluate the efficacy and safety of lymphocyte immunotherapy (LIT) with aspirin, LIT with human chorionic gonadotropin (hCG), LIT with joint hCG and aspirin, and LIT alone for patients with unexplained recurrent spontaneous abortion (URSA). Methods This retrospective cohort study included all consecutive patients with URSA in 2009—2014 in a tertiary care hospital. Patients were excluded if they had not become pregnant within 1 year after the end of LIT or their medical records were not complete. The rates of successful pregnancy and live birth were determined between the alone LIT group (group A, n=61), LIT with aspirin (group B, n=109), LIT with hCG (group C, n=35) and LIT with joint hCG and aspirin (group D, n=65). The factors that influenced these pregnancy outcomes were identified by multiple Logistical regression analysis. The partum maternal and neonatal complications were recorded. Results Compared with group A (59.0%), group B (75.2%), group C (82.9%) and group D (83.1%) had significantly higher rates of successful pregnancy (P<0.05). Compared with group A (55.7%), group B (71.6%), group C (82.9%) and group D (80.0%) had significantly higher rates of live birth (P<0.05). There was no statistical significance of the successful pregnancy rate and live birth rate among group B, group C and group D. The risk of maternal complications in group D (7.69%) relatively increased (0.00%, 0.92%, 0.00% in groups A-C, respectively). Conclusion LIT with aspirin, LIT with hCG, LIT with joint hCG and aspirin improved the pregnancy outcomes of patients with URSA, which deserved more clinical recognition and application. The future study to evaluate the safety of LIT with joint hCG and aspirin is warranted. Key words: Unexplained recurrent spontaneous abortion (URSA); Lymphocyte immunotherapy; Aspirin; Human chorionic gonadotropin (hCG); Combined therapy